AstraZeneca, HutchMed's MET inhibitor Orpathys scores first global nod in China for rare lung cancer

Retrieved on: 2021-06-23 15:25:32

Tags for this article:

Click the tags to see associated articles and topics

AstraZeneca, HutchMed's MET inhibitor Orpathys scores first global nod in China for rare lung cancer. View article details on hiswai:

Excerpt

Ten years AstraZeneca partnered with HutchMed, formerly known as Chi-Med, on a promising cancer treatment, the association has paid dividends ...

Article found on: www.fiercepharma.com